NASDAQ$TECX
Tectonic Therapeutic Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
AVROBIO reported financial results for the quarter ended June 30, 2021 and provided a business update.
AVROBIO reported a net loss of $31.4 million for the second quarter of 2021, driven by increased research and development expenses as well as increased general and administrative expenses. As of June 30, 2021, AVROBIO had $226.4 million in cash and cash equivalents.
- FDA granted Fast Track Designation to AVR-RD-04 for cystinosis.
- The company is planning to initiate multiple registration trials in 2022.
- Multiple data and regulatory updates are anticipated over the next 12 months.
- Two additional patients have been dosed in the FAB-GT trial since June 2021.
Headline financials
Revenue & EPS history
Tectonic · Revenue · Quarterly
$0
Forward guidance
Based on the company’s current operating plan, AVROBIO expects its cash and cash equivalents as of June 30, 2021 will enable the company to fund its operating expenses and capital expenditure requirements into the first quarter of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2021
-1.4%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+2.9%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+11.1%
Q4 2021
Best reaction
-20.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.4% | +14.5% | +22.6% | |
| Q3 2025 | +1.5% | -0.7% | +4.9% | |
| Q1 2025 | -0.9% | +3.5% | -13.4% | |
| Q4 2024 | +1.0% | -11.8% | +11.0% | |
| Q3 2024 | -2.0% | +6.5% | +14.8% | |
| Q1 2024 | +0.0% | -0.8% | -7.0% | |
| Q4 2023 | +0.8% | -2.3% | -1.6% | |
| Q3 2023 | -9.9% | -13.2% | -7.2% | |
| Q2 2023 | +0.6% | -1.9% | +4.5% | |
| Q1 2023 | -4.5% | -4.5% | +82.1% | |
| Q4 2022 | -20.3% | -14.6% | -23.6% | |
| Q3 2022 | -1.5% | +12.1% | +19.7% | |
| Q2 2022 | +5.0% | +5.9% | -12.9% | |
| Q1 2022 | -7.3% | -1.2% | +30.5% | |
| Q4 2021 | +11.1% | +12.5% | -20.8% | |
| Q3 2021 | -1.0% | -3.8% | -40.7% | |
| Q2 2021 | +6.5% | -17.0% | -13.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro